💥 This Tiny Biotech Could Break Out in 2026

Multiple shots on goal, breakthrough results, and massive 2026 potential ahead! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from Interactive Offers   

NanoViricides (NYSE: NNVC) is Set to Redefine Antiviral Therapy in 2026: NV-387 Targets Measles, Respiratory Viruses, MPox, and Biodefense Threats with Phase II Trials on the Horizon

NanoViricides (NYSE: NNVC) is a clinical-stage biotech on the verge of a major breakthrough with its lead antiviral, NV-387: a revolutionary therapy designed to attack viruses directly while protecting vital organs from immune-mediated damage.

With measles cases surging across the U.S. and vaccination gaps widening, NV-387 has already demonstrated dramatic survival benefits and lung protection in humanized animal models. Phase I trials confirmed its safety and tolerability, and the drug is conveniently available as oral gummies, ideal for patients experiencing severe viral symptoms.

NV-387's nanoviricide technology and "Re-Infection Inhibition" mechanism create a broad-spectrum antiviral platform capable of addressing not only measles but also influenza, RSV, COVID-19, H5N1, MPox, and smallpox, positioning NNVC as a potentially dominant player in the antiviral market.

NNVC is advancing Phase II development through a dual-track strategy to maximize speed and impact. Track 1 targets MPox in Congo with an ethically approved Phase II trial, offering potential U.S. biodefense support through BARDA.

Track 2 is a "basket-type" trial in India addressing multiple respiratory viruses, including influenza, RSV, and coronaviruses, with potential start in Winter 2026, creating a pathway to U.S. trials in 2027.

Analysts estimate billions in addressable markets across RSV, influenza, and biodefense applications, highlighting NV-387's extraordinary commercial potential.

With its proven clinical profile, broad-spectrum capabilities, and imminent Phase II trials, NNVC is strategically positioned for rapid growth and may become one of 2026's defining biotech stories.

Learn why NNVC is primed for breakout growth, with NV-387 ready to transform antiviral therapy and capitalize on urgent global viral threats.




Today's editorial pick for you

3 Stocks to Watch After Analyst Upgrades


Posted On Nov 13, 2025 by Chris Markoch

It's always a good idea for investors to track analyst upgrades. That’s because these investing professionals usually have access to a company’s financial data and executive team at a level most retail investors never enjoy.

Analyst upgrades and price revisions are influenced by:

  1. Company fundamentals, such as financial health, future growth, and even meetings with management
  2. Industry and market trends, including specific market conditions and economics.
  3. Earnings and financial data, including earnings reports that came in better than expected, or competitive analysis of a competitor, and guidance.
  4. They may be piling into a stock based on interest from other firms. 

However, you should never rely solely on analyst upgrades when deciding whether to buy a stock. Instead, pay attention to what's happening technically 
and fundamentally. The last thing you want to do is buy into a recently upgraded, but overvalued stock. That's a great way to lose money. 

Here are some of the stocks with recent analyst upgrades you may want to consider. 

Stocks with Analyst Upgrades: Penn Entertainment (PENN) 

Stifel upgraded Penn Entertainment Inc. (NASDAQ: PENN) to a Buy rating, with a price target of $21 a share. That’s approximately 50% above the PENN stock price as of this writing. This follows its termination of its sports betting agreement with ESPN earlier than planned. 

"When we first announced our partnership with ESPN, both sides made it clear that we expected to compete for a podium position in the space," said Jay Snowden, CEO and President of PENN Entertainment, in a company press release. 

"Although we made significant progress in improving our product offering and building a cohesive ecosystem with ESPN, we have mutually and amicably agreed to wind down our collaboration. We plan to realign our digital focus on our growing iCasino business, while continuing to capitalize on our omnichannel advantage as the nation's leading regional retail casino operator," he added. 

Stocks with Analyst Upgrades: Nvidia (NVDA) 

Analysts at Bernstein reiterated an outperform rating on Nvidia Corp. (NASDAQ: NVDA) ahead of earnings and said NVDA is a key player in the robotic chip market. 

Loop Capital reiterated its buy rating on the tech giant and hiked its price target to $350 from $250. The firm believes NVDA can double its GPU shipments over the next year to 15 months to 2.1 million by the January 2026 quarter. 

Goldman Sachs reiterated its buy rating on NVDA with a price target of $240 from $210 ahead of earnings, as well. The firm believes investor expectations have risen heading into NVDA's earnings, driven by multiple AI infrastructure announcements.

The firm also believes the company will deliver another beat-and-raise quarter. Also helping Nvidia is news that Microsoft secured export licenses from the Trump Administration to ship NVDA chips to the United Arab Emirates. 

Stocks with Analyst Upgrades: Snap (SNAP) 

Deutsche Bank just reiterated its buy rating on Snap Inc. (NYSE: SNAP), raising its price target to $12 from $9. That’s about 50% higher than the SNAP stock price as of this writing.

The firm noted that SNAP's partnership with Perplexity AI is a strong step toward building out alternative revenue streams. Snap also reported strong revenue that was above expectations while saying it would buy back $500 million worth of stock. 

The company also announced a new partnership with Perplexity, a company that develops an AI search engine, which will be featured on the Snapchat app. In doing so, Perplexity will pay Snap $400 million over the course of a year, which will be split between cash and stock. 




This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Nov 14, 2025 and Nov 20, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on equiscreen website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS

StockEarnings.com



Post a Comment

Previous Post Next Post

Contact Form